Identificación de una población de bien dotados

[Resumen] Este artículo recoge la identificación de sujetos bien dotados en los cursos de Primera (6-12 años) y 10 ciclos de ESO (13-14 años) en cinco centros públicos de la comunidad autónoma de España y para ello se construye una matriz de rasgos característicos de la población de bien dotados, que se les ha pasado a expertos de educación para preseleccionar a la muestra del estudio. Posteriorlnente se les aplicará los Test de Matrices Progresivas de Raven y el de AMPE.[Abstract] In this article we have pretended to identificate gifted children in the courses of Prünary (6-12 years old) and 10 cicle of secundary (13-14 years old) in five public centers of the Autonomy Comunity of Spain and for that we have elaborated a matrix to detected caracterist lines in the population of gifteg children. Fot that we have copilated the dates and give them to the exports of Education with the idea of preselection a sampling of our study. Tem we will apply severd tests like Progressive Matrix ofRaven and the AMPE (Secadas, 1961

Síndrome de Rett: identificación de una patología en nuestras aulas

[Resumen] Todavía no se ha establecido una adecuada orientación en el potencial de aprendizaje de los niños con Síndrome de Rett. (A.V.S.R.,1995). Por ello, pretendeInos exponer en este trabajo un enfoque dedicado a las estrategias de intervención u orientación, que ya han sido utilizadas con algunas niñas de forIna experimental en otros paises con relativo éxito. SabeInos que este síndrome afecta a las niñas, esta ligado al cromosoma X, que su reconocimiento y tratamiento como patología data de la década de los 60 cuando el profesor neuropsiquiatra Rett descubrió que en la sala de su consulta había dos niñas, que estaban haciendo el mismo movimiento estereotipado y decidió prestar atención a lo que les sucedía, dándole posteriormente, su nombre al síndrome que estudió tan detenidamente

Propuesta en Supply Chain Management y Logística en la empresa Tecnitrauma S.A

Durante el diplomado de profundización se llevó a cabo el análisis operacional de la empresa Tecnitrauma S.A la cual tiene sede en la ciudad de Barranquilla/Atlántico y en donde uno de los objetivos principales era el análisis e implementación de mejoras en los elementos del modelo referencial de las cadenas de suministro y Logística. Esta empresa es prestadora de servicios médicos especializados y está enfocada en el campo de la traumatología en donde ofrecen productos relacionados sobre Ortesis y Osteosíntesis. Al abordar los distintos elementos del diplomado se pudo evidenciar mejoras en los procesos operacionales los cuales se documentaron y de iguales formas algunas ya se encontraban en operación y se procedió a su actualización. Este proceso fue llevado a cabo por el grupo 24 del curso de Diplomado de Supply Chain Management y Logística de la UNAD y fue posible concluirlo gracias a la disposición, conocimiento y entrega de cada uno de los presentes y sobre todo al acompañamiento recibido por la Universidad.During the in-depth diploma, the operational analysis of the company Tecnitrauma S.A, which is based in the city of Barranquilla/Atlántico, was carried out, where one of the main objectives was the analysis and implementation of improvements in the elements of the model Reference of the supply chains and Logistics. This company is a provider of specialized medical services and is focused in the field of traumatology where they offer related products on Orthosis and Osteosynthesis. By addressing the different elements of the diploma, it was possible to show improvements in the operational processes that were documented and in the same way some were already in operation and they were updated. This process was carried out by the 24th group of the UNAD Supply Chain Management and Logistics Diploma course and it was possible to conclude it thanks to the willingness, knowledge and dedication of each of those present and especially the accompaniment received by the University

HGF, IL-1α, and IL-27 are robust biomarkers in early severity stratification of COVID-19 patients

© 2021 by the authors.Pneumonia is the leading cause of hospital admission and mortality in coronavirus disease 2019 (COVID-19). We aimed to identify the cytokines responsible for lung damage and mortality. We prospectively recruited 108 COVID-19 patients between March and April 2020 and divided them into four groups according to the severity of respiratory symptoms. Twenty-eight healthy volunteers were used for normalization of the results. Multiple cytokines showed statistically significant differences between mild and critical patients. High HGF levels were associated with the critical group (OR = 3.51; p < 0.001; 95%CI = 1.95–6.33). Moreover, high IL-1α (OR = 1.36; p = 0.01; 95%CI = 1.07–1.73) and low IL-27 (OR = 0.58; p < 0.005; 95%CI = 0.39–0.85) greatly increased the risk of ending up in the severe group. This model was especially sensitive in order to predict critical status (AUC = 0.794; specificity = 69.74%; sensitivity = 81.25%). Furthermore, high levels of HGF and IL-1α showed significant results in the survival analysis (p = 0.033 and p = 0.011, respectively). HGF, IL-1α, and IL 27 at hospital admission were strongly associated with severe/critical COVID-19 patients and therefore are excellent predictors of bad prognosis. HGF and IL-1α were also mortality biomarkers.This work was supported by the Carlos III Health Institute (Grant COV20/00491)

HGF, IL-1α, and IL-27 Are Robust Biomarkers in Early Severity Stratification of COVID-19 Patients

Producción CientíficaPneumonia is the leading cause of hospital admission and mortality in coronavirus disease 2019 (COVID-19). We aimed to identify the cytokines responsible for lung damage and mortality. We prospectively recruited 108 COVID-19 patients between March and April 2020 and divided them into four groups according to the severity of respiratory symptoms. Twenty-eight healthy volunteers were used for normalization of the results. Multiple cytokines showed statistically significant differences between mild and critical patients. High HGF levels were associated with the critical group (OR = 3.51; p < 0.001; 95%CI = 1.95–6.33). Moreover, high IL-1α (OR = 1.36; p = 0.01; 95%CI = 1.07–1.73) and low IL-27 (OR = 0.58; p < 0.005; 95%CI = 0.39–0.85) greatly increased the risk of ending up in the severe group. This model was especially sensitive in order to predict critical status (AUC = 0.794; specificity = 69.74%; sensitivity = 81.25%). Furthermore, high levels of HGF and IL-1α showed significant results in the survival analysis (p = 0.033 and p = 0.011, respectively). HGF, IL-1α, and IL 27 at hospital admission were strongly associated with severe/critical COVID-19 patients and therefore are excellent predictors of bad prognosis. HGF and IL-1α were also mortality biomarkers.Instituto de Salud Carlos III (grant COV20/00491

The new multi-frequency instrument (MFI2) for the QUIJOTE facility in Tenerife

The QUIJOTE (Q-U-I joint Tenerife) experiment combines the operation of two radio-telescopes and three instruments working in the microwave bands 10?20 GHz, 26-36 GHz and 35-47 GHz at the Teide Observatory, Tenerife, and has already been presented in previous SPIE meetings (Hoyland, R. J. et al, 2012; Rubiño-Martín et al., 2012). The Cosmology group at the IAC have designed a new upgrade to the MFI instrument in the band 10-20 GHz. The aim of the QUIJOTE telescopes is to characterise the polarised emission of the cosmic microwave background (CMB), as well as galactic and extra-galactic sources, at medium and large angular scales. This MFI2 will continue the survey at even higher sensitivity levels. The MFI2 project led by the Instituto de Astrofísica de Canarias (IAC) consists of five polarimeters, three of them operating in the sub-band 10?15 GHz, and two in the sub-band 15-20 GHz. The MFI2 instrument is expected to be a full two-three times more sensitive than the former MFI. The microwave complex correlator design has been replaced by a simple correlator design with a digital back-end based on the latest Xilinx FPGAs (ZCU111). During the first half of 2019 the manufacture of the new cryostat was completed and since then the opto-mechanical components have been designed and manufactured. It is expected that the cryogenic front-end will be completed by the end of 2022 along with the FPGA acquisition and observing system. This digital system has been employed to be more robust against stray ground-based and satellite interference, having a frequency resolution of 1 MHz.The MFI2 instrument is being developed by the Instituto de Astrofisica de Canarias (IAC), with an instrumental participation from the Universidad Politecnica de Cartagena (UPCT). Partial financial support is provided by the Spanish Ministry of Science and Innovation (MICINN), under the projects AYA2017-84185-P, IACA15-BE-3707, EQC2018-004918-P and the FEDER Agreement INSIDE-OOCC (ICTS-2019-03-IAC-12). We also acknowledge financial support of the Severo Ochoa Programs SEV-2015-0548 and CEX2019-000920-S

Can the Cytokine Profile According to ABO Blood Groups Be Related to Worse Outcome in COVID-19 Patients? Yes, They Can

Producción CientíficaSevere status of coronavirus disease 2019 (COVID-19) is extremely associated to cytokine release. Moreover, it has been suggested that blood group is also associated with the prevalence and severity of this disease. However, the relationship between the cytokine profile and blood group remains unclear in COVID-19 patients. In this sense, we prospectively recruited 108 COVID-19 patients between March and April 2020 and divided according to ABO blood group. For the analysis of 45 cytokines, plasma samples were collected in the time of admission to hospital ward or intensive care unit and at the sixth day after hospital admission. The results show that there was a risk of more than two times lower of mechanical ventilation or death in patients with blood group O (log rank: p = 0.042). At first time, all statistically significant cytokine levels, except from hepatocyte growth factor, were higher in O blood group patients meanwhile the second time showed a significant drop, between 20% and 40%. In contrast, A/B/AB group presented a maintenance of cytokine levels during time. Hepatocyte growth factor showed a significant association with intubation or mortality risk in non-O blood group patients (OR: 4.229, 95% CI (2.064–8.665), p < 0.001) and also was the only one bad prognosis biomarker in O blood group patients (OR: 8.852, 95% CI (1.540–50.878), p = 0.015). Therefore, higher cytokine levels in O blood group are associated with a better outcome than A/B/AB group in COVID-19 patients.Instituto de Salud Carlos III (grant COV20/00491)Junta de Castilla y León (grant 18IGOF

Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) had an estimated overall case fatality ratio of 1.38% (pre-vaccination), being 53% higher in males and increasing exponentially with age. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, we found 133 cases (1.42%) with detectable clonal mosaicism for chromosome alterations (mCA) and 226 males (5.08%) with acquired loss of chromosome Y (LOY). Individuals with clonal mosaic events (mCA and/or LOY) showed a 54% increase in the risk of COVID-19 lethality. LOY is associated with transcriptomic biomarkers of immune dysfunction, pro-coagulation activity and cardiovascular risk. Interferon-induced genes involved in the initial immune response to SARS-CoV-2 are also down-regulated in LOY. Thus, mCA and LOY underlie at least part of the sex-biased severity and mortality of COVID-19 in aging patients. Given its potential therapeutic and prognostic relevance, evaluation of clonal mosaicism should be implemented as biomarker of COVID-19 severity in elderly people. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, individuals with clonal mosaic events (clonal mosaicism for chromosome alterations and/or loss of chromosome Y) showed an increased risk of COVID-19 lethality

Impact of COVID-19 on cardiovascular testing in the United States versus the rest of the world

Objectives: This study sought to quantify and compare the decline in volumes of cardiovascular procedures between the United States and non-US institutions during the early phase of the coronavirus disease-2019 (COVID-19) pandemic. Background: The COVID-19 pandemic has disrupted the care of many non-COVID-19 illnesses. Reductions in diagnostic cardiovascular testing around the world have led to concerns over the implications of reduced testing for cardiovascular disease (CVD) morbidity and mortality. Methods: Data were submitted to the INCAPS-COVID (International Atomic Energy Agency Non-Invasive Cardiology Protocols Study of COVID-19), a multinational registry comprising 909 institutions in 108 countries (including 155 facilities in 40 U.S. states), assessing the impact of the COVID-19 pandemic on volumes of diagnostic cardiovascular procedures. Data were obtained for April 2020 and compared with volumes of baseline procedures from March 2019. We compared laboratory characteristics, practices, and procedure volumes between U.S. and non-U.S. facilities and between U.S. geographic regions and identified factors associated with volume reduction in the United States. Results: Reductions in the volumes of procedures in the United States were similar to those in non-U.S. facilities (68% vs. 63%, respectively; p = 0.237), although U.S. facilities reported greater reductions in invasive coronary angiography (69% vs. 53%, respectively; p < 0.001). Significantly more U.S. facilities reported increased use of telehealth and patient screening measures than non-U.S. facilities, such as temperature checks, symptom screenings, and COVID-19 testing. Reductions in volumes of procedures differed between U.S. regions, with larger declines observed in the Northeast (76%) and Midwest (74%) than in the South (62%) and West (44%). Prevalence of COVID-19, staff redeployments, outpatient centers, and urban centers were associated with greater reductions in volume in U.S. facilities in a multivariable analysis. Conclusions: We observed marked reductions in U.S. cardiovascular testing in the early phase of the pandemic and significant variability between U.S. regions. The association between reductions of volumes and COVID-19 prevalence in the United States highlighted the need for proactive efforts to maintain access to cardiovascular testing in areas most affected by outbreaks of COVID-19 infection